Introduction .
Purpose .
The primary endpoint is overall survival ,  secondaryendpoints are disease-free survival ,  rate of loco-regionalrecurrence ,  and treatment-related toxicity/morbidity .
Materials and methods .
Patients excluded included those with recurrent cancer ,  or with second malignancy (except non-melanomatous skin cancer and in-situ cervical cancer) ,  active infection ,  pregnant or nursing women .
Dosage schedule .
